Ny Teknik & Affärsvärlden list SenzaGen AB as one of the 33 most promising young innovative companies in Sweden

On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden after winning Lund local elevator pitch for NyTeknik and Affärsvärlden 33-list.

After several interviews by the organisers, a challenging questioning by an initiated jury and a smashing elevator pitch, Senzagen acquired a position on the renowned 33-list.

The 33-list is based on propositions of companies from all over Sweden and the winners are chosen collectively by the editorial staff at the two journals Ny Teknik and Affärsvärlden. The jury is looking for companies with a unique product or service based on a clear innovation with great international potential – an innovation with the ability to change the rules in the business. To qualify for a position on the list, the company must be based in Sweden and be less than 7 years. Read more on (in Swedish) http://www.33-listan.se 

Link to the article in Ny Teknik 2015, March 2: http://www.nyteknik.se/33listan/article3889772.ece (Swedish)

For more information
Anki Malmborg Hager, 0768-284 822, amh@senzagen.com
SenzaGen AB, www.senzagen.com

About Us

About SenzaGen SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.




Documents & Links